Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference
Rhea-AI Summary
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on Wednesday, August 14, 2024, at 3:00pm Eastern Time.
This presentation marks an important opportunity for Neuronetics to showcase its progress and future plans to investors and industry professionals. The event will be accessible via a live audio webcast on the investor relations page of Neuronetics' website at ir.neuronetics.com, allowing interested parties to tune in remotely.
As a company focused on improving the quality of life for patients with neurohealth disorders, Neuronetics' participation in this conference could provide valuable insights into their latest developments and market strategies.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, STIM gained 1.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When is Neuronetics (STIM) presenting at the Canaccord Genuity 44th Annual Growth Conference?
How can I access Neuronetics' (STIM) presentation at the Canaccord Genuity conference?
What is the focus of Neuronetics (STIM) as a medical technology company?
Where is Neuronetics (STIM) headquartered?
